Protein Kinase Inhibitors for Renal Cell Carcinoma

Protein kinase inhibitors for renal cell carcinoma represent a targeted therapeutic drug class consisting primarily of small-molecule receptor tyrosine kinase inhibitors These agents work principally by inhibiting vascular endothelial growth factor receptors, along with other key kinase pathways such as platelet-derived growth factor receptor, MET, and AXL By disrupting these downstream intracellular signaling cascades, they impair tumor-associated angiogenesis, cellular proliferation, and metas...

Protein kinase inhibitors for renal cell carcinoma represent a targeted therapeutic drug class consisting primarily of small-molecule receptor tyrosine kinase inhibitors

These agents work principally by inhibiting vascular endothelial growth factor receptors, along with other key kinase pathways such as platelet-derived growth factor receptor, MET, and AXL

The primary clinical indication for this class is advanced or metastatic renal cell carcinoma, where these drugs are utilized as monotherapy or combined with immune checkpoint inhibitors, and they may also offer therapeutic utility across other vascularized malignancies